Cogent Biosciences Stock Soars: A Year of Gains and a $4.5M Sell
Cogent Biosciences has delivered staggering gains in a single year, yet a major fund recently trimmed its stake by mi...
When To Switch From Target Date Fund To Age Based Approach: Go. This intro covers when a switch makes sense and what signals to watch for in your plan.
25,368 articlesCogent Biosciences has delivered staggering gains in a single year, yet a major fund recently trimmed its stake by mi...
VanEck's GENZ pivots from casino-heavy holdings to growth stocks like Uber and NetEase, reshaping its dividend story ...
A top hedge fund stepping up its Duolingo stake highlights conviction in the language-learning platform. This article...
A new income-focused ETF challenger has pushed past JEPI by roughly 42 percentage points since its October 2023 debut...
An ESG equity fund has posted a double-digit gain while steering clear of Meta. Its AI-forward lineup centers on Alph...
A 58-year-old nurse with 230K saved is advised to buy a condo and ramp retirement funding, with a potential 350K inhe...
XCEM has risen 38% year-to-date, beating the S&P 500 by a wide margin as investors tilt toward emerging markets ex-Ch...
Analysts released a wave of Friday calls on major names, lifting some stocks and easing others as markets digest the ...
Two top analysts trimmed DoorDash price targets after the company posted solid Q1 results, while signaling a brighter...
California voters will decide this November on a one-time 5% wealth tax aimed at billionaires to shore up Medicaid fu...
EWY has surged in 2026 on AI-driven demand for memory chips, attracting a growing cohort of retirees into the play. T...
A softer-than-expected 2027 COLA can catch households off guard. This guide shows how to adjust your budget now with ...